Szczęsny TJ, Kanarkiewicz M, Kowalewski J. Screening for lung cancer with chest computerized tomography: Is it cost efficient? World J Respirol 2015; 5(2): 160-165 [DOI: 10.5320/wjr.v5.i2.160]
Corresponding Author of This Article
Tomasz Jarosław Szczęsny, MD, PhD, Department of Thoracic Surgery and Tumors, Oncology Center in Bydgoszcz, Romanowskiej Str. 2, 85-796 Bydgoszcz, Poland. szczesny@lungcancer.med.pl
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jul 28, 2015 (publication date) through Nov 1, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Respirology
ISSN
2218-6255
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Szczęsny TJ, Kanarkiewicz M, Kowalewski J. Screening for lung cancer with chest computerized tomography: Is it cost efficient? World J Respirol 2015; 5(2): 160-165 [DOI: 10.5320/wjr.v5.i2.160]
World J Respirol. Jul 28, 2015; 5(2): 160-165 Published online Jul 28, 2015. doi: 10.5320/wjr.v5.i2.160
Screening for lung cancer with chest computerized tomography: Is it cost efficient?
Tomasz Jarosław Szczęsny, Małgorzata Kanarkiewicz, Janusz Kowalewski
Tomasz Jarosław Szczęsny, Janusz Kowalewski, Department of Thoracic Surgery and Tumors, Oncology Center in Bydgoszcz, 85-796 Bydgoszcz, Poland
Małgorzata Kanarkiewicz, Department of Pharmaceutical Technology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, 85-796 Bydgoszcz, Poland
Janusz Kowalewski, Department of Thoracic Surgery and Neoplasms, Medical Faculty in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-796 Bydgoszcz, Poland
Author contributions: All authors contributed to the writing of the manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Tomasz Jarosław Szczęsny, MD, PhD, Department of Thoracic Surgery and Tumors, Oncology Center in Bydgoszcz, Romanowskiej Str. 2, 85-796 Bydgoszcz, Poland. szczesny@lungcancer.med.pl
Telephone: + 48-52-3743574 Fax: +48-52-3743436
Received: November 24, 2014 Peer-review started: November 26, 2014 First decision: January 8, 2015 Revised: February 6, 2015 Accepted: April 8, 2015 Article in press: April 9, 2015 Published online: July 28, 2015 Processing time: 253 Days and 7 Hours
Core Tip
Core tip: Results of prospective, randomized trial finally provided the evidence that lung cancer screening with computerized tomography prolongs survival of the screened population. Several cost-effectiveness analyses were performed to justify mass introduction of this screening, but their results differ between countries. Cost-effectiveness depends especially upon the rate of false-positive results which increase the number of unnecessary medical procedures. Therefore, to ensure high cost-effectiveness, lung cancer screening should be performed in accordance with screening protocol, in dedicated screening centers equipped with nodule volume change analysis, or as a prospective non-randomized trial, to ensure compliance with the inclusion and exclusion criteria.
